2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Pathology, Bioinformatics, Gene Editing, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Non-Biological Therapies, Pharmacology, Women’s Health, Artificial Intelligence (AI), Biological Processes, Pathogenesis, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Genetic Disorders, Immunology, Autoimmune Disorders, Metabolic Disorders, Iron Deficiency, Iron Overload, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Pregnant, Animal Model
PAPER

1123 Anti-hemojuvelin monoclonal antibody reverses anemia and exerts disease-modifying effects in an adoptive T-cell transfer inflammatory bowel disease mouse model

Julia Xu, PhD, Min Wu, PhD2
1 Disc Medicine, Watertown, Massachusetts, United States
2 Disc Medicine, Watertown, Massachusetts, United States

Background: Selcodebart (DISC-0974) is an investigational anti-hemojuvelin (HJV) monoclonal antibody designed to disrupt HJV-mediated activation of the bone morphogenetic protein (BMP) receptor complex in the liver, thereby suppressing hepcidin expression and increasing iron availability for enhanced erythropoiesis. Selcodebart is currently being evaluated in clinical studies for anemia associated with myelofibrosis (NCT05320198) and inflammatory bowel disease (IBD) (NCT07368972).

Anemia is the most common complication of IBD, and is caused by chronic inflammation, iron deficiency, intestinal blood loss, and/or impaired iron absorption. Anemia of inflammation remains difficult to manage in many patients. Previously, we demonstrated that DBIO-100, a murine surrogate of selcodebart, reversed anemia while also exhibiting disease-modifying effects on chronic colitis in a dextran sodium sulfate (DSS)-induced colitis model (Xu et al, Blood 2024). This study evaluated the efficacy of DBIO-100 in an adoptive T-cell transfer model that recapitulates key features of Crohn’s disease and ulcerative colitis.

Methods: Female Rag2-/- mice maintained on a 50 ppm iron diet received intraperitoneal transfer of either CD4+CD45Rbhigh T cells to induce IBD or CD4+CD45Rblow T cells as healthy controls. Three weeks after the T-cell transfer, mice were randomized to receive either vehicle or DBIO-100 (20 mg/kg intravenously every week). Cohort 1 was evaluated after 15 days of treatment, and Cohort 2 after 29 days.

Results: Adoptive T-cell transfer induced severe colitis, characterized by marked weight loss, elevated disease activity index (DAI), and mild anemia of inflammation. Compared with the healthy controls, the T-cell transfer IBD mice exhibited a 2.2 g/dL reduction in hemoglobin (Hgb). DBIO-100 increased Hgb by 2.8 g/dL relative to the T-cell transfer IBD mice. Consistent with its mechanism of action, DBIO-100 reduced serum hepcidin levels and increased serum iron and transferrin saturation (TSAT).

Beyond correction of anemia, DBIO-100 demonstrated disease-modifying activities, including attenuated body weight loss, lower DAI scores, restoration in colon length, improved ileum and colon histopathology, and reduced circulating pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-6. Temporal analysis demonstrated that the improvements in serum iron, DAI, and inflammatory cytokines were evident after 15 days of treatment (Cohort 1), and maximal improvements in Hgb, TSAT, and colon length were observed following 29 days of treatment (Cohort 2).

Conclusions: DBIO-100, a murine anti-HJV monoclonal antibody, not only reversed anemia, but also produced broad, disease-modifying effects in 2 complementary preclinical models of IBD, including DSS-induced colitis and the T-cell transfer model; the latter captures pathological features of Crohn’s disease and ulcerative colitis. These findings demonstrate that by lowering hepcidin, HJV inhibition improves anemia and iron homeostasis while attenuating inflammation and supports the continued clinical development of selcodebart for the treatment of anemia associated with chronic inflammatory diseases, including IBD.

Julia Xu, PhD: Disc Medicine - Current equity holder in publicly-traded company; Disc Medicine - Stock (publicly traded); Disc Medicine - Divested equity in a private or publicly-traded company in the past 24 months; Disc Medicine - Current Employment